Paper37372147
Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications.
Georgoulis V and 4 others. Biology (Basel), 2023. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications. Papers, record 37372147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37372147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References119
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34615710 | Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34615710 | PubMed |
| 2 | 24547707 | Plasmacytoid dendritic cell and CD4 + T cell deficiencies in untreated Hodgkin disease: implications for susceptibility to opportunistic infections. | Leuk Lymphoma | 2014 | https://conductscience.org/library/papers/24547707 | PubMed |
| 3 | 28115586 | Pillars Article: Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science 2003. 299: 1057-1061. | J Immunol | 2017 | https://conductscience.org/library/papers/28115586 | PubMed |
| 4 | 22271878 | Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22271878 | PubMed |
| 5 | 29080383 | Clinical significance of tryptophan catabolism in Hodgkin lymphoma. | Cancer Sci | 2018 | https://conductscience.org/library/papers/29080383 | PubMed |
| 6 | 31304817 | Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment. | Leuk Lymphoma | 2019 | https://conductscience.org/library/papers/31304817 | PubMed |
| 7 | 24886161 | Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. | BMC Cancer | 2014 | https://conductscience.org/library/papers/24886161 | PubMed |
| 8 | 29796651 | Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Ann Oncol | 2018 | https://conductscience.org/library/papers/29796651 | PubMed |
| 9 | 32043750 | Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer. | Cancer Med | 2020 | https://conductscience.org/library/papers/32043750 | PubMed |
| 10 | 26991548 | Prognostic significance of CD169-positive lymph node sinus macrophages in patients with endometrial carcinoma. | Cancer Sci | 2016 | https://conductscience.org/library/papers/26991548 | PubMed |
| 11 | 32019558 | The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt. | Diagn Pathol | 2020 | https://conductscience.org/library/papers/32019558 | PubMed |
| 12 | 18924115 | Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. | Hematol Oncol | 2009 | https://conductscience.org/library/papers/18924115 | PubMed |
| 13 | 17438085 | Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. | Blood | 2007 | https://conductscience.org/library/papers/17438085 | PubMed |
| 14 | 25098425 | High CD20+ background cells predict a favorable outcome in classical Hodgkin lymphoma and antagonize CD68+ macrophages. | Leuk Lymphoma | 2015 | https://conductscience.org/library/papers/25098425 | PubMed |
| 15 | 12612581 | An essential role for Scurfin in CD4+CD25+ T regulatory cells. | Nat Immunol | 2003 | https://conductscience.org/library/papers/12612581 | PubMed |
| 16 | 27733075 | The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy<sup/>. | Leuk Lymphoma | 2017 | https://conductscience.org/library/papers/27733075 | PubMed |
| 17 | 36215668 | Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management. | Am J Hematol | 2022 | https://conductscience.org/library/papers/36215668 | PubMed |
| 18 | 28002629 | Possible functions of CD169-positive sinus macrophages in lymph nodes in anti-tumor immune responses. | Cancer Sci | 2017 | https://conductscience.org/library/papers/28002629 | PubMed |
| 19 | 35327381 | Macrophage Infiltration Correlates with Genomic Instability in Classic Hodgkin Lymphoma. | Biomedicines | 2022 | https://conductscience.org/library/papers/35327381 | PubMed |
| 20 | 31694167 | Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31694167 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42294290 | Evolution of therapeutic paradigms in Hodgkin lymphoma: from "cure-oriented" to "functional cure". | Front Oncol | 2026 | https://conductscience.org/library/papers/42294290 | PubMed |
| 42049433 | Expression Patterns of T-cell immunoreceptor With Ig and ITIM domains (TIGIT) in Classical Hodgkin Lymphoma: A Clinicopathological Study. | In Vivo | 2026 | https://conductscience.org/library/papers/42049433 | PubMed |
| 42027746 | Predictors of sensitivity to immune therapies in classic Hodgkin lymphoma. | Blood Neoplasia | 2026 | https://conductscience.org/library/papers/42027746 | PubMed |
| 41975693 | The Prognostic Significance of the Systemic Inflammation Response Index (SIRI) and HALP Score in Hodgkin's Lymphoma. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/41975693 | PubMed |
| 41799502 | Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma. | Oncol Res | 2026 | https://conductscience.org/library/papers/41799502 | PubMed |
| 40806636 | Metabolic Interactions in the Tumor Microenvironment of Classical Hodgkin Lymphoma: Implications for Targeted Therapy. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40806636 | PubMed |
| 40361408 | Epstein-Barr Infection, Hodgkin's Lymphoma, and the Immune System: Insights into the Molecular Mechanisms Facilitating Immune Evasion. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40361408 | PubMed |
| 39057061 | Unraveling the Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic and Potential Therapeutic Implications. | Curr Issues Mol Biol | 2024 | https://conductscience.org/library/papers/39057061 | PubMed |
| 38779660 | Mesenchymal stem cells-macrophages crosstalk and myeloid malignancy. | Front Immunol | 2024 | https://conductscience.org/library/papers/38779660 | PubMed |
| 38534975 | Expression Patterns of GATA3 in Classical Hodgkin Lymphoma: A Clinico-Pathological Study. | Diseases | 2024 | https://conductscience.org/library/papers/38534975 | PubMed |
| 38090582 | Broadening the horizon: potential applications of CAR-T cells beyond current indications. | Front Immunol | 2023 | https://conductscience.org/library/papers/38090582 | PubMed |
Genes76
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37372147
GET https://conductscience.org/api/papers/v1/37372147/references?page=2